Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis (NCT01670565), a randomized phase 2 study. The primary outcome is Change in Modified Rodnan Skin Score (MRSS).

2. Clinical Question

This is a question about adding belimumab to a shared MMF treatment background, not a comparison of belimumab with no treatment. Because both groups received MMF, the randomized comparison is intended to distinguish the outcomes observed with belimumab infusion from those observed with placebo infusion under the study conditions. The posted MRSS summaries describe the change within each group; they do not, by themselves, establish the uncertainty around a between-group effect.

3. Trial Design

The registry describes a phase 2a, single-center, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept pilot study. Enrollment is listed as 20. The two randomized groups are mycophenolate mofetil plus belimumab and mycophenolate mofetil plus saline placebo. The posted arm summaries list 10 participants in each group.

The treatment sequence matters when interpreting the comparison. According to the study summary, all participants first received MMF, titrated to a dose of 2 grams per day. After this period, participants received either belimumab or placebo infusion. Thus the study examines the addition of an infusion assignment after an MMF lead-in, rather than belimumab as a stand-alone treatment. The record describes the placebo infusion as normal saline and says it appeared identical to the belimumab infusion.

Random allocation is intended to make assigned groups comparable on average, while masking is intended to reduce the influence of treatment knowledge on care and assessment. These design features support a controlled comparison, but they do not eliminate uncertainty in a pilot study or replace a reported analysis. The registry does not report details of the randomization procedure, allocation concealment, or which trial personnel were masked.

The brief study summary describes a 48 week study, while the primary outcome timeframe is listed as baseline and at 52 weeks. The registry record does not explain this difference. The study is marked completed, with start recorded as 2012-08 and primary completion as 2015-11. These registry fields describe study conduct and timing; they do not establish that every enrolled participant completed follow-up or contributed to each outcome.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Modified Rodnan Skin Score (MRSS), measured over Baseline and at 52 weeks.

The primary endpoint is change in Modified Rodnan Skin Score (MRSS), summarized as a median change with interquartile range, from baseline to 52 weeks. MRSS is a clinical assessment of dermal skin thickness across 17 body areas. Each area is scored from 0 for uninvolved skin to 3 for severe thickening, and the total is the sum of the area scores. The possible total score ranges from 0 to 51, with higher scores indicating greater disease severity.

Skin thickness is used in this study as a measure of cutaneous disease activity. A change score focuses on how the measured score moves over the follow-up period rather than only describing the score at one time point. A lower score at follow-up relative to baseline is a decrease in measured skin thickening on this scale. The endpoint therefore gives a structured way to compare the observed skin-score changes in the two randomized groups.

The posted median change is -10 in the belimumab-plus-MMF group, with reported bounds of -13 to -9, and -3 in the placebo-plus-MMF group, with reported bounds of -15 to -1. The registry identifies the dispersion as an interquartile range. These summaries describe the distributions within each group; they are not a confidence interval for the treatment contrast. The record does not report a separate between-group estimate or its uncertainty for this endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistics in a randomized trial answer different questions. A group summary describes the outcomes observed among participants assigned to that group. A between-group estimate addresses how outcomes compare across assignments. A measure of uncertainty then indicates how compatible the data are with a range of possible underlying comparisons. The registry's median changes are group summaries; they do not supply all three pieces for a treatment comparison.

What does a median change describe?

A median is a measure of the center of a distribution. It is the middle observation when values are ordered, rather than an arithmetic average. A median can be useful when a distribution is skewed or when a small number of unusual values might pull an average. Here, the endpoint is explicitly summarized using median change and interquartile range. That tells the reader that the reported central value and spread are based on the distribution of individual changes, rather than a mean and standard deviation.

A change score is formed by comparing an individual's measurement at follow-up with that individual's baseline measurement. The reported median summarizes those participant-level changes within a group. It is not necessarily equal to the difference between the group median at baseline and the group median at follow-up. The registry describes the endpoint as median change from baseline to week 52, and reports the group-level median change.

What does an interquartile range tell the reader?

The interquartile range describes the central half of a distribution, bounded by its lower and upper quartiles. It conveys variation in observed participant changes. It is not a measure of the precision of the group median in the same way a confidence interval is, and it is not a confidence interval for a difference between treatment groups. The endpoint record identifies the dispersion as an interquartile range and gives bounds for each group's median summary.

When interquartile ranges overlap, that fact alone does not determine whether a between-group comparison is statistically significant. Conversely, a comparison of group medians and their ranges does not provide a formal test. A comparative analysis must use the trial data and a stated method to estimate the contrast and its uncertainty. No such result is listed in the registry record.

Why distinguish group changes from a treatment contrast?

Each group's change can reflect more than the assigned infusion. Both groups received MMF, and outcomes may also vary over time for reasons shared by both groups or by chance. Randomization supports comparing assignments, but the relevant estimate is a contrast between groups, interpreted under the analysis plan and population used. Looking at change in one group alone does not isolate the contribution of the added infusion.

A confidence interval for a between-group estimate would describe the range of effects reasonably compatible with the data under the analysis assumptions. A p-value would describe how unusual the observed data, or more extreme data, would be under a specified null hypothesis and model. Neither statistic is reported for the primary outcome in the registry information. No confidence level, test result, or adjustment for baseline is reported, so none should be inferred from the medians and interquartile ranges.

What can a planning calculation show?

Sample-size planning uses assumptions about the outcome variability, the effect a future study aims to detect, the significance level, and the desired power. Such calculations are design illustrations, not results about participants in the completed trial. The registry's planning assumptions describe a two-sided significance level of 0.05, equal allocation, and a normal approximation; the intended effect is expressed as a fraction of the observed effect. These assumptions are not reported as the trial's own design justification. The record does not report a sample-size justification or the resulting planning quantities in the registry record for this account.

Power is a property of a planned study under specified assumptions, not a retrospective measure of whether an observed result is reliable. A calculation based on an observed effect should not be described as observed power. In particular, the registry's planning illustration does not convert the posted medians into a formal treatment effect or resolve the lack of a reported comparative analysis.

Why can over-dispersion matter?

As a general statistical point, over-dispersion occurs when observed variability is greater than a chosen model expects. If a model assumes too little variation, its standard errors may be too small and its uncertainty intervals too narrow. Appropriate modeling may need to allow for the actual spread in the data. The registry information does not report a model for the MRSS comparison or whether over-dispersion was assessed; this general issue should not be taken to imply that it occurred in this trial.

More generally, a choice between a model-based analysis and a distribution-free approach depends on the outcome distribution, design, and estimand. Median summaries do not reveal which inferential method was used. Since the registry lists no analyses, the statistical procedure for the primary comparison is not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 7 outcome measures overall and identifies 3 secondary outcomes: change in the Scleroderma Health Assessment Questionnaire Disability Index, change in the mental component summary of the Short Form-36 questionnaire, and change in its physical component summary. The primary outcome is change in MRSS. The presence of several outcomes raises a general multiplicity issue: when many hypotheses are assessed, the chance of at least one apparently unusual result can increase. Whether and how to address that issue depends on the prespecified analysis plan.

Multiplicity procedures, a hierarchy for outcome testing, and the statistical analysis plan are not reported in the registry record. The record lists no analyses, so it does not provide inferential results for the primary or secondary outcomes to assess for multiplicity. The other outcome measures beyond those named are not described in the registry record for this account.

The posted information also does not report missing-data methods, the number of participants with evaluable MRSS measurements at each time point, or reasons for missing measurements. It does not identify an intention-to-treat, per-protocol, or other analysis population. Enrollment and arm summaries do not establish that every randomized participant had an observed 52-week outcome. Without the analysis population and missing-data approach, the reader cannot determine how incomplete follow-up was handled or how sensitive results might be to that handling.

These omissions do not show that missing data or multiplicity affected the findings; they mean that the registry record does not describe how those issues were addressed. Interpretation should therefore remain limited to the posted group summaries.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: anxiety attack (10.0%), chest pain (10.0%), dyspnea (10.0%).

The registry lists serious adverse events affecting 0 participants in the mycophenolate mofetil plus belimumab group and 2 participants in the mycophenolate mofetil plus saline placebo group. The posted groups each list 10 participants at risk for serious adverse events. No deaths are listed in either group. These are participant counts, not rates calculated for a different follow-up period or exposure time.

The record also lists other adverse events affecting 9 participants in each group, among 10 at risk in each group. Serious and other adverse events are separate categories in the posted record and should not be added together; an individual may be represented in more than one category, and the record does not provide participant-level overlap. The terms Anxiety Attack, Chest Pain, and Dyspnea are listed among the top serious terms, each with a reported value of 10.0%. The information available does not identify a group for each term or explain whether these terms refer to events or affected participants.

These safety counts are descriptive. They do not establish comparative risk, causation, or the absence of unreported events. The registry record does not provide further detail about event timing, duration, severity grading, exposure time, or the criteria used to classify events as serious. The small group summaries should therefore be read as the recorded counts, not as a complete safety assessment.

12. What the Result Does, and Does Not, Mean

The primary outcome data describe MRSS changes observed within the two randomized groups. The median change was -10 with belimumab plus MMF and -3 with placebo plus MMF; the associated reported interquartile-range bounds were -13 to -9 and -15 to -1, respectively. Because a higher MRSS indicates greater disease severity, negative changes represent decreases in the measured score. These summaries are descriptive and do not include a formal estimate of the difference between assigned groups.

The result does not establish that belimumab caused a change in MRSS. The registry record does not report a between-group effect estimate, confidence interval, p-value, or statistical analysis for the primary outcome. It also does not report a clinically important threshold for interpreting score changes. The group medians cannot answer those questions on their own, and the ranges are interquartile ranges rather than uncertainty intervals for a treatment contrast.

The result also does not establish effects on the listed secondary outcomes. The record names changes in disability and in the mental and physical components of the Short Form-36, but does not report their results in the registry record. Nor do the posted safety counts alone provide a complete assessment of comparative safety.

The study's design and scope should remain part of the interpretation. It was a randomized, double-blind, placebo-controlled phase 2a pilot study at a single center, with enrollment of 20. The findings describe the participants and observations represented in the registry record, not necessarily a broader population. Details about eligibility, follow-up completeness, analysis populations, and missing-data methods are not reported in the registry record.

In short, the posted numbers show the reported group-level MRSS changes and adverse-event counts. They do not supply the inferential or methodological information needed to make a definitive comparative claim. A reader should distinguish what was observed from what a formal analysis would estimate, and should not treat the planning illustration as evidence of the study's observed power.

13. Why This Trial Matters Statistically

This trial is statistically instructive because it separates a within-group change from the randomized comparison of interest. Both groups received MMF, while the infusion assignment differed. The scientific question is therefore about the additional assignment to belimumab relative to placebo on that shared treatment background. Reporting a median change for each group is informative, but a comparative estimate and its uncertainty are needed to quantify the contrast.

The use of a median and interquartile range also highlights the importance of matching summaries to the data. These measures describe the center and spread of observed changes without requiring the reader to assume that values follow a symmetric distribution. They should not, however, be mistaken for a confidence interval or a statistical test. Different summaries answer different questions.

The trial's pilot and single-center features make precision and generalizability important considerations. A small pilot can provide descriptive information and inform future research, but a small set of group summaries may leave substantial uncertainty. The record does not report the statistical analysis plan or a formal comparison, so the precision of the treatment contrast cannot be judged from the posted endpoint summaries.

Finally, the registry illustrates why transparency about analysis populations, missing data, and multiple outcomes matters. Those details help readers understand which observations support a result and how many statistical questions were addressed. They are not reported in the registry record for this account. The most defensible statistical reading is consequently bounded: describe the posted outcomes, distinguish them from inferential claims, and identify the information needed for a fuller assessment.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to the posted registry information constrain interpretation. The trial is described as a phase 2a proof-of-concept pilot at a single center, and enrollment is listed as 20. The available record does not provide detailed eligibility criteria, so the exact population to which the observations apply cannot be characterized beyond early diffuse cutaneous systemic sclerosis.

The primary endpoint timeframe is baseline and 52 weeks, whereas the brief study summary describes a 48 week study. The registry record does not explain this timing difference. The primary outcome description states that results are median change with interquartile range, but does not provide a formal between-group estimate or inferential analysis. The listed group bounds therefore cannot establish the uncertainty of the comparative effect.

The registry does not report the randomization procedure, allocation concealment, full masking details, statistical analysis plan, analysis population, or handling of missing data. It also does not report whether the primary analysis was adjusted for baseline MRSS, how secondary outcomes were analyzed, or how multiplicity was addressed. These omissions do not establish that the trial methods were inadequate; they limit what can be assessed from the registry record.

Although adverse-event counts are posted, additional information about event timing, exposure, severity grading, and participant-level overlap is not available in the registry record. The listed serious-event terms are not connected to a specific group in the information provided. Safety interpretation is therefore limited to the recorded group counts and terms.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis — NCT01670565.
• Registry record last updated 2022-05-24; status last verified 2022-05.
• Results first posted 2022-05-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record identifies NCT01670565 as a completed phase 2a, randomized, double-blind, parallel-group, placebo-controlled proof-of-concept pilot study of belimumab for diffuse cutaneous systemic sclerosis. It lists Hospital for Special Surgery, New York, as sponsor, enrollment of 20, a start date of 2012-08, and primary completion of 2015-11.

Participants first received MMF, titrated to 2 grams per day, followed by belimumab infusion or saline placebo infusion. The primary outcome was change in MRSS from baseline to 52 weeks, summarized by median and interquartile range. The posted median changes were -10 for belimumab plus MMF and -3 for placebo plus MMF. The record lists 3 secondary outcomes and 7 outcome measures overall, but lists no analyses. It also records serious adverse events affecting 0 participants in the belimumab group and 2 in the placebo group, with no deaths listed in either group.